DDR1 and DDR2: a review on signaling pathway and small molecule inhibitors as an anticancer agent
Gurubasavaraja Swamy Purawarga Matada(Drug Discovery Laboratory (Norway)), Abhishek Ghara(Unknown), Prasad Sanjay Dhiwar(Mahatma Gandhi Mission Institute of Health Sciences), Arka Das(Rajiv Gandhi University of Health Sciences)
Cited by 35
Related Papers
Molecular docking and molecular dynamic studies: screening of phytochemicals against EGFR, HER2, estrogen and NF-KB receptors for their potential use in breast cancer
|Journal of Biomolecular Structure and Dynamics|2021|37
Benzothiazole a privileged scaffold for Cutting-Edges anticancer agents: Exploring drug design, structure-activity relationship, and docking studies
|European Journal of Medicinal Chemistry|2024|32
An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief review
|Journal of Biomolecular Structure and Dynamics|2023|28
An updated literature on BRAF inhibitors (2018–2023)
|Molecular Diversity|2023|24
Management of COVID-19-induced cytokine storm by Keap1-Nrf2 system: a review
|Inflammopharmacology|2021|21